Clinical trials: SBS
Short Bowel Syndrome
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.
- Trial name
- NCT00930644
- Testing
- teduglutide
- Where
- 23 sites in United States, Canada and 7 more
- Volunteers
- 88 people
- Sponsor
- Shire
Short Bowel Syndrome
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
- Trial name
- EASE SBS 2 (NCT03905707)
- Testing
- glepaglutide
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 150 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS).
- Trial name
- EASE SBS 4 (NCT04991311)
- Testing
- Glepaglutide
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Survival and PN Dependence in SBS Patients
Short bowel syndrome (SBS) is a rare condition resulting from the loss of portions of the small intestine, and can cause a spectrum of metabolic and physiologic disturbances.The objective of this study was to determine the…
- Trial name
- NCT06102668
- Volunteers
- 173 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Leishmaniasis, Cutaneous Leishmaniasis
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Intralesional injection of antimony has been used for L major from Iran with a modest cure rate [56%: Asilian 2004]. However, this therapeutic approach has been used for L braziliensis from Brazil, with an attractive cure rate…
- Trial name
- NCT01300975
- Testing
- pentavalent antimony, cryotherapy
- Where
- 2 sites in Bolivia
- Volunteers
- 90 people
- Sponsor
- Fundacion Nacional de Dermatologia
Leishmaniasis, Cutaneous, Helminthiasis
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
The purpose of this project is to investigate the efficacy of early, empiric anti-helminthic therapy combined with standard pentavalent antimony in the treatment of subjects co-infected with helminths and cutaneous leishmaniasis…
- Trial name
- NCT00469495
- Testing
- Anti-helminthic, meglumine antimony
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Short Bowel Syndrome
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN…
- Trial name
- NCT00742157
- Testing
- Growth Hormone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Arthritis
Study Comparing SBS and LRTI for Treatment of CMC Arthritis
A multi-center, randomized control trial comparing the two standard of care surgical treatments for CMC arthritis ; trapezial excision with or without soft tissue interposition and /or ligament reconstruction (LRTI) versus the…
- Trial name
- SBSvsLRTI (NCT05111405)
- Testing
- CMC Arthroplasty
- Where
- 2 sites in Canada
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Fraser Orthopaedic Research Society
Short Bowel Syndrome
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
- Trial name
- STARS extend (NCT05018286)
- Testing
- Apraglutide
- Where
- 66 sites in United States, Argentina and 16 more
- Volunteers
- 158 people
- Sponsor
- VectivBio AG
Cutaneous Leihmaniasis
Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia
The combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and antimony is chosen because these are now the two standard agents in…
- Trial name
- NCT00537953
- Testing
- Miltefosine , meglumine antimoniate
- Where
- Bolivia
- Sponsor
- Centro de Investigaciones Bioclínicas de la Fundación Fader
Short Bowel Syndrome
Proof of Concept Study in Patients With Short Bowel Syndrome
This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide.
- Trial name
- NCT04379856
- Testing
- NM-002
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- 9 Meters Biopharma, Inc.
Blood Platelet Disorders
Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
The term MYH9-related disease (MYH9RD) includes four genetic disorders: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome.
- Trial name
- NCT01133860
- Testing
- eltrombopag
- Where
- 3 sites in Italy
- Volunteers
- 12 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Leishmaniasis, Mucocutaneous
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
The purpose of this study is to evaluate the safety of the Leish-111f + MPL-SE vaccine given as three injections every 28 days at each of three dose levels of Leish-111f protein, in combination with standard pentavalent antimony…
- Trial name
- NCT00111514
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- 2 sites in Peru
- Volunteers
- 48 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leishmaniasis
Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
Cutaneous leishmaniasis is endemic in the New World and, until recently, the standard treatment was pentavalent antimony. The cure rate for L panamensis in Colombia is 91%-93% and the cure rate in Bolivia is also 90%.
- Trial name
- NCT01380301
- Testing
- Miltefosine and antimony, Miltefosine alone
- Where
- Bolivia
- Volunteers
- 19 people
- Sponsor
- Foundation Fader
Short Bowel Syndrome
A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021
This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.
- Trial name
- STEPS3 (NCT01560403)
- Testing
- Teduglutide
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shire